Advertisement

Managing Challenging Behaviour in Brain Tumour (BT) Patients

  • Wolfgang Grisold
  • Simon Grisold
  • Alla Guekht
  • Roberta Ruda
Chapter

Abstract

Managing patients with brain tumours is not confined to best surgical, radiotherapeutic and chemotherapeutic practices, but also involves the management of behavioural changes that arise from different causes and at different time points of the disease.

These behavioural changes need to be managed and considered from different perspectives; they can also affect the patient’s interactions with health care professionals and carers and can affect the patient’s social interactions.

This chapter will discuss four main causes of behavioural disorders in patients with brain tumours, which can be (1) due to focal or diffuse brain damage, (2) psychiatric effects (3) seizures, (4) the effects of tumour treatment and the overlapping of several different causes.

The time course of malignant brain tumours is usually stereotyped and involves the time of diagnosis, the treatment period, a phase of progression with cognitive decline and an end-of-life phase.

The behavioural changes of brain tumour patients are important not only for the patients and their carers, but also for their interactions with health care professionals and other social contacts. Although the behavioural changes can be directly caused by the strategic localization of the brain tumour, several other causes need to be considered and defined in regard to the selection of therapeutic interventions.

Notes

Conflict of Interest

The authors report no conflict of interest and have contributed equally to the chapter.

References

  1. 1.
    Madhusoodanan S, Ting MB, Farah T, Ugur U. Psychiatric aspects of brain tumors: a review. World J Psychiatry. 2015;5:273–85.CrossRefGoogle Scholar
  2. 2.
    Kübler-Ross E. On death and dying. London: Routledge; 1969. ISBN 0-415-04015-9.Google Scholar
  3. 3.
    Andrewes DG, Kaye A, Murphy M, Harris B, Aitken S, Parr C, Bates L. Emotional and social dysfunction in patients following surgical treatment for brain tumour. J Clin Neurosci. 2003;10:428–33.CrossRefGoogle Scholar
  4. 4.
    Cavers D, Hacking B, Erridge SE, Kendall M, Morris PG, Murray SA. Social, psychological and existential well-being in patients with glioma and their caregivers: a qualitative study. CMAJ. 2012;184:E373–82.CrossRefGoogle Scholar
  5. 5.
    Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol. 1993;50:873–80.CrossRefGoogle Scholar
  6. 6.
    Lucas MR. Psychosocial implications for the patient with a high-grade glioma. J Neurosci Nurs. 2010;42:104–8.CrossRefGoogle Scholar
  7. 7.
    Sterckx W, Coolbrandt A, Dierckx de Casterle B, Van den Heede K, Decruyenaere M, Borgenon S, Mees A, Clement P. The impact of a high-grade glioma on everyday life: a systematic review from the patient’s and caregiver’s perspective. Eur J Oncol Nurs. 2013;17:107–17.CrossRefGoogle Scholar
  8. 8.
    Fuster JM. The prefrontal cortex – an update: time is of the essence. Neuron. 2001;30:319–33.CrossRefGoogle Scholar
  9. 9.
    Gregg N, Arber A, Ashkan K, Brazil L, Bhangoo R, Beaney R, Gullan R, Hurwitz V, Costello A, Yaguez L. Neurobehavioural changes in patients following brain tumour: patients and relatives perspective. Support Care Cancer. 2014;22:2965–72.CrossRefGoogle Scholar
  10. 10.
    Nasrallah HA, Mcchesney CM. Psychopathology of corpus callosum tumors. Biol Psychiatry. 1981;16:663–9.PubMedGoogle Scholar
  11. 11.
    Schmahmann JD. Disorders of the cerebellum: ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome. J Neuropsychiatry Clin Neurosci. 2004;16:367–78.CrossRefGoogle Scholar
  12. 12.
    Campanella F, Shallice T, Ius T, Fabbro F, Skrap M. Impact of brain tumour location on emotion and personality: a voxel-based lesion-symptom mapping study on mentalization processes. Brain. 2014;137:2532–45.CrossRefGoogle Scholar
  13. 13.
    Oberndorfer S, Urbanits S, Lahrmann H, Kirschner H, Kumpan W, Grisold W. Akinetic mutism caused by bilateral infiltration of the fornix in a patient with astrocytoma. Eur J Neurol. 2002;9:311–3.CrossRefGoogle Scholar
  14. 14.
    Bourdillon P, Apra C, Lévêque M, Vinckier F. Neuroplasticity and the brain connectome: what can Jean Talairach’s reflections bring to modern psychosurgery? Neurosurg Focus. 2017;43(3):E11.  https://doi.org/10.3171/2017.6.FOCUS17251.CrossRefPubMedGoogle Scholar
  15. 15.
    Levine PM, Silberfarb PM, Lipowski ZJ. Mental disorders in cancer patients: a study of 100 psychiatric referrals. Cancer. 1978;42:1385–91.CrossRefGoogle Scholar
  16. 16.
    Boele FW, Rooney AG, Grant R, Klein M. Psychiatric symptoms in glioma patients: from diagnosis to management. Neuropsychiatr Dis Treat. 2015;11:1413–20.CrossRefGoogle Scholar
  17. 17.
    Betul O, Ipek M. Brain tumor presenting with psychiatric symptoms. J Neuropsychiatry Clin Neurosci. 2011;23:E43–4.CrossRefGoogle Scholar
  18. 18.
    Madhusoodanan S, Opler MG, Moise D, Gordon J, Danan DM, Sinha A, Babu RP. Brain tumor location and psychiatric symptoms: is there any association? A meta-analysis of published case studies. Expert Rev Neurother. 2010;10:1529–36.CrossRefGoogle Scholar
  19. 19.
    Uribe VM. Psychiatric symptoms and brain tumor. Am Fam Physician. 1986;34:95–8.PubMedGoogle Scholar
  20. 20.
    Munjal S, Pahlajani S, Baxi A, Ferrando S. Delayed diagnosis of glioblastoma multiforme presenting with atypical psychiatric symptoms. Prim Care Companion CNS Disord. 2016;18:6.Google Scholar
  21. 21.
    Pool JL, Correll JW. Psychiatric symptoms masking brain tumor. J Med Soc N J. 1958;55:4–9.PubMedGoogle Scholar
  22. 22.
    Mardaga S, Al Bassir M, Bracke J, Dutilleux A, Born JD. Which psychiatric symptoms must raise suspicion about a possible brain tumor? Rev Med Liege. 2017;72:399–405.PubMedGoogle Scholar
  23. 23.
    Filley CM, Kleinschmidt-Demasters BK. Neurobehavioral presentations of brain neoplasms. West J Med. 1995;163:19–25.PubMedPubMedCentralGoogle Scholar
  24. 24.
  25. 25.
    Annegers JF, Rocca WA, Hauser WA. Causes of epilepsy: contributions of the Rochester epidemiology project. Mayo Clin Proc. 1996;71:570–5.CrossRefGoogle Scholar
  26. 26.
    Kasper BS, Kasper EM. New classification of epilepsy-related neoplasms: the clinical perspective. Epilepsy Behav. 2017;67:91–7.CrossRefGoogle Scholar
  27. 27.
    Rahman Z, Wong CH, Dexter M, Olsson G, Wong M, Gebsky V, Nahar N, Wood A, Byth K, King M, Bleasel AB. Epilepsy in patients with primary brain tumors: the impact on mood, cognition, and HRQOL. Epilepsy Behav. 2015;48:88–95.CrossRefGoogle Scholar
  28. 28.
    Delgado-Escueta AV, Mattson RH, King L, Goldensohn ES, Spiegel H, Madsen J, Crandall P, Dreifuss F, Porter RJ. Special report. The nature of aggression during epileptic seizures. N Engl J Med. 1981;305:711–6.CrossRefGoogle Scholar
  29. 29.
    Van Elst LT, Woermann FG, Lemieux L, Thompson PJ, Trimble MR. Affective aggression in patients with temporal lobe epilepsy: a quantitative MRI study of the amygdala. Brain. 2000;123(Pt 2):234–43.CrossRefGoogle Scholar
  30. 30.
    Andermann LF, Savard G, Meencke HJ, Mclachlan R, Moshe S, Andermann F. Psychosis after resection of ganglioglioma or DNET: evidence for an association. Epilepsia. 1999;40:83–7.CrossRefGoogle Scholar
  31. 31.
    Guimaraes CA, Franzon RC, Souza EA, Schmutzler KM, Montenegro MA, Queiroz Lde S, Cendes F, Guerreiro MM. Abnormal behavior in children with temporal lobe epilepsy and ganglioglioma. Epilepsy Behav. 2004;5:788–91.CrossRefGoogle Scholar
  32. 32.
    Brinkman TM, Liptak CC, Delaney BL, Chordas CA, Muriel AC, Manley PE. Suicide ideation in pediatric and adult survivors of childhood brain tumors. J Neuro-Oncol. 2013;113:425–32.CrossRefGoogle Scholar
  33. 33.
    Hecimovic H, Salpekar J, Kanner AM, Barry JJ. Suicidality and epilepsy: a neuropsychobiological perspective. Epilepsy Behav. 2011;22:77–84.CrossRefGoogle Scholar
  34. 34.
    Casazza M, Gilioli I. Non-convulsive status epilepticus in brain tumors. Neurol Sci. 2011;32(Suppl 2):S237–9.CrossRefGoogle Scholar
  35. 35.
    Cavaliere R, Farace E, Schiff D. Clinical implications of status epilepticus in patients with neoplasms. Arch Neurol. 2006;63:1746–9.CrossRefGoogle Scholar
  36. 36.
    Hormigo A, Liberato B, Lis E, DeAngelis LM. Non-convulsive status epilepticus in patients with cancer: imaging abnormalities. Arch Neurol. 2004;61:362–5.CrossRefGoogle Scholar
  37. 37.
    Rheims S, Ricard D, Van den Bent M, Taillandier L, Bourg V, Desestret V, Cartalat-Carel S, Hermier M, Monjour A, Delattre JY, Sanson M, Honnorat J, Ducray F. Peri-ictal pseudoprogression in patients with brain tumor. Neuro-Oncology. 2011;13:775–82.CrossRefGoogle Scholar
  38. 38.
    Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. Neuro-Oncology. 2015;17:488–504.CrossRefGoogle Scholar
  39. 39.
    Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, Detyniecki K. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76:24–31.CrossRefGoogle Scholar
  40. 40.
    Piedad J, Rickards H, Besag FM, Cavanna AE. Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations. CNS Drugs. 2012;26:319–35.CrossRefGoogle Scholar
  41. 41.
    Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2007;10:105–10.CrossRefGoogle Scholar
  42. 42.
    Roth P, Happold C, Weller M. Corticosteroid use in neuro-oncology: an update. Neuro-Oncol Pract. 2015;22(1):6–12.CrossRefGoogle Scholar
  43. 43.
    Lee EQ, Wen PY. Corticosteroids for peritumoral edema: time to overcome our addiction? Neuro-Oncology. 2016;18:1191–2.CrossRefGoogle Scholar
  44. 44.
    Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998;25:39–47.PubMedGoogle Scholar
  45. 45.
    Simoa M, Rifa-Rosa X, Rodriguez-Fornellsa A, Bruna J. Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev. 2013;37(8):1311–21.Google Scholar
  46. 46.
    Behrend SW. Patients with primary brain tumors. Oncol Nurs Forum. 2014;41:335–6.CrossRefGoogle Scholar
  47. 47.
    Gaman AM, Uzoni A, Popa-Wagner A, Andrei A, Petcu EB. The role of oxidative stress in etiopathogenesis of chemotherapy induced cognitive impairment (CICI)-“Chemobrain”. Aging Dis. 2016;7:307–17.CrossRefGoogle Scholar
  48. 48.
    Kamiya-Matsuoka C, Cachia D, Olar A, Armstrong TS, Gilbert MR. Primary brain tumors and posterior reversible encephalopathy syndrome. Neurooncol Pract. 2014;1:184–90.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Golomb BA, Koslik HJ, Redd AJ. Fluoroquinolone-induced serious, persistent, multisymptom adverse effects. BMJ Case Rep. 2015;2015:bcr2015209821.  https://doi.org/10.1136/bcr-2015-209821.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Estfan B, Yavuzsen T, Davis M. Development of opioid-induced delirium while on olanzapine: a two-case report. J Pain Symptom Manag. 2005;29:330–2.CrossRefGoogle Scholar
  51. 51.
    Swart LM, Van der Zanden V, Spies PE, de Rooij SE, Van Munster BC. The comparative risk of delirium with different opioids: a systematic review. Drugs Aging. 2017;34:437–43.CrossRefGoogle Scholar
  52. 52.
    Mollazadeh-Moghaddam K, Jamali A, Adili-Aghdam F, Akhondzadeh S. Delirium associated with donepezil in a patient with Alzheimer’s disease: a case report. Iran J Psychiatry. 2013;8:59–60.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Jors K, Tietgen S, Xander C, Momm F, Becker G. Tidying rooms and tending hearts: an explorative, mixed-methods study of hospital cleaning staff’s experiences with seriously ill and dying patients. Palliat Med. 2017;31(1):63–71.CrossRefGoogle Scholar
  54. 54.
    Moore DP. Textbook of clinical neuropsychiatry. London: Hodder Arnold; 2008.CrossRefGoogle Scholar
  55. 55.
    Pompili A, Telera S, Villani V, Pace A. Home palliative care and end of life issues in glioblastoma multiforme: results and comments from a homogeneous cohort of patients. Neurosurg Focus. 2014;37(6):E5.  https://doi.org/10.3171/2014.9.FOCUS14493.CrossRefPubMedGoogle Scholar
  56. 56.
    Bush SH, Kanji S, Pereira JL, Davis DHJ, Currow DC, Meagher D, Rabheru K, Wright D, Bruera E, Hartwick M, Gagnon PR, Gagnon B, Breitbart W, Regnier L, Lawlor PG. Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development. J Pain Symptom Manag. 2014;48:231–48.CrossRefGoogle Scholar
  57. 57.
    Pace A, Dirven L, Koekkoek JAF, Golla H, Fleming J, Ruda R, Marosi C, Le Rhun E, Grant R, Oliver K, Oberg I, Bulbeck HJ, Rooney AG, Henriksson R, Pasman HRW, Oberndorfer S, Weller M, Taphoorn MJB, European Association of Neuro-Oncology Palliative Care Task Force. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol. 2017;18:e330–40.CrossRefGoogle Scholar
  58. 58.
    Kissane DW, Clarke DM, Street AF. Demoralization syndrome – a relevant psychiatric diagnosis for palliative care. J Palliat Care. 2001;17:12–21.PubMedGoogle Scholar
  59. 59.
    Somasundaram RO, Devamani KA. A comparative study on resilience, perceived social support and hopelessness among cancer patients treated with curative and palliative care. Indian J Palliat Care. 2016;22:135–40.CrossRefGoogle Scholar
  60. 60.
    Kübler-Ross E. On grief and grieving: finding the meaning of grief through the five stages of loss. London: Simon & Schuster; 2005.Google Scholar
  61. 61.
    Adelbratt S, Strang P. Death anxiety in brain tumour patients and their spouses. Palliat Med. 2000;14:499–507.CrossRefGoogle Scholar
  62. 62.
    Ramirez AJ. Liaison psychiatry in a breast cancer unit. J R Soc Med. 1989;82:15–7.CrossRefGoogle Scholar
  63. 63.
    De Giorgio G, Quartesan R, Sciarma T, Giulietti M, Piazzoli A, Scarponi L, Ferrari S, Ferranti L, Moretti P, Piselli M. Consultation-Liaison Psychiatry-from theory to clinical practice: an observational study in a general hospital. BMC Res Notes. 2015;8:475.CrossRefGoogle Scholar
  64. 64.
    Fearey P, Collier B, DeMarco T. A defined process for project post mortem review. Browse J Mag IEEE Softw. 1996;13(4):65–72.  https://doi.org/10.1109/52.526833.CrossRefGoogle Scholar
  65. 65.
    Cetrano G, Tedeschi F, Rabbi L, Gosetti G, Lora A, Lamonaca D, Manthorpe J, Amaddeo F. How are compassion fatigue, burnout, and compassion satisfaction affected by quality of working life? Findings from a survey of mental health staff in Italy. BMC Health Serv Res. 2017;17:755.  https://doi.org/10.1186/s12913-017-2726-x.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Ma C. The importance of debriefing in clinical simulations. Clin Simul Nurs. 2008;4(2):e19–23.  https://doi.org/10.1016/j.ecns.2008.06.006.CrossRefGoogle Scholar
  67. 67.
    Keene EA, Hutton N, Hall B, Rushton C. Bereavement debriefing sessions: an intervention to support health care professionals in managing their grief after the death of a patient. Pediatr Nurs. 2010;36:185–9. quiz 190.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Wolfgang Grisold
    • 1
  • Simon Grisold
    • 2
  • Alla Guekht
    • 3
  • Roberta Ruda
    • 4
  1. 1.Ludwig Boltzmann Institute for Experimental und Clinical TraumatologyViennaAustria
  2. 2.Sozialpsychiatrisches Ambulatorium LandstraßeViennaAustria
  3. 3.Moscow Research and Clinical Center for Neuropsychiatry and Russian National Research Medical UniversityMoscowRussia
  4. 4.Department of Neuro-OncologyUniversity and City of Health and Science Hospital of TurinTurinItaly

Personalised recommendations